Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Geoffrey Chan"'
Autor:
John Silwanus Kaku, Riris Andono Ahmad, Stephanie Main, Dwi Oktofiana, Bintari Dwihardiani, Rina Triasih, Philipp du Cros, Geoffrey Chan
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 9, Iss 4, p 75 (2024)
Active-case finding (ACF) using chest X-ray is an essential method of finding and diagnosing Tuberculosis (TB) cases that may be missed in Indonesia’s routine TB case finding. This study compares active and passive TB case-finding strategies. A ret
Externí odkaz:
https://doaj.org/article/25be33f9e6ee4c268d0e78d125c249c5
Autor:
Betty Nababan, Rina Triasih, Geoffrey Chan, Bintari Dwihardiani, Arif Hidayat, Setyogati C. Dewi, Lana Unwanah, Arif Mustofa, Philipp du Cros
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 9, Iss 2, p 34 (2024)
In Indonesia, the implementation of tuberculosis (TB) contact investigation is limited, with low detection rates. We report the yield of and risk factors for TB disease and infection for household contacts (HHCs) investigated using chest X-ray (CXR)
Externí odkaz:
https://doaj.org/article/3debddd7ba9243598ee61202296e5215
Autor:
Felisia Felisia, Rina Triasih, Betty Weri Yolanda Nababan, Guardian Yoki Sanjaya, Setyogati Candra Dewi, Endang Sri Rahayu, Lana Unwanah, Philipp du Cros, Geoffrey Chan
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 8, Iss 12, p 520 (2023)
Coverage of tuberculosis preventive treatment (TPT) in Indonesia is inadequate, and persons who start TPT often do not complete treatment. In 2020, Zero TB Yogyakarta implemented person-centered contact investigation and shorter TPT regimen provision
Externí odkaz:
https://doaj.org/article/c18ce305572d485cb1ef885625da71b5
Autor:
Geoffrey Chan, J. Douglas Storey, Manoja Kumar Das, Emma Sacks, Mira Johri, Tamar Kabakian-Khasholian, Deepak Paudel, Sachiyo Yoshida, Anayda Portela
Publikováno v:
Health Research Policy and Systems, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background Social, behavioural and community engagement (SBCE) interventions are essential for global maternal, newborn and child health (MNCH) strategies. Past efforts to synthesise research on SBCE interventions identified a need for clear
Externí odkaz:
https://doaj.org/article/07cb57389b244e01bed2d5f355c0ae4a
Autor:
Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized
Externí odkaz:
https://doaj.org/article/eb1cbed6f88d4b89add1a17240cfd403
Publikováno v:
Journal of Pathology Informatics, Vol 13, Iss , Pp 100143- (2022)
Background: In the clinical laboratory, middleware is a software application that sits between the analyzer and the laboratory information system (LIS). One of the more common uses of middleware is to perform more efficient result autoverification th
Externí odkaz:
https://doaj.org/article/aaa96fb6ea4140bd8d2edfcd8cd8d97b
Autor:
Jorge E. Cortes, Geoffrey Chan, Ashleigh O'Connell, Mirjana Zeremski, A. Douglas Laird, M. Naveed Shaik, Weidong Wendy Ma, Hagop M. Kantarjian, James McCloskey, Jeffrey Lancet, Mark A. Schroeder, Vivian G. Oehler, Wendy Stock, Daniel A. Pollyea, Michael R. Savona
Purpose: This open-label, multicenter, dose-finding, phase Ib study (NCT01546038) evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the novel Hedgehog pathway Smoothened inhibitor glasdegib (PF-04449913) in patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe667682407264cca4df8cd19f3fd28
https://doi.org/10.1158/1078-0432.c.6525722.v1
https://doi.org/10.1158/1078-0432.c.6525722.v1
Autor:
Jorge E. Cortes, Geoffrey Chan, Ashleigh O'Connell, Mirjana Zeremski, A. Douglas Laird, M. Naveed Shaik, Weidong Wendy Ma, Hagop M. Kantarjian, James McCloskey, Jeffrey Lancet, Mark A. Schroeder, Vivian G. Oehler, Wendy Stock, Daniel A. Pollyea, Michael R. Savona
Additional Methods: MTD determination; Biomarker analyzed Supplementary Table S1. Patient disposition by treatment group Supplementary Table S2. Treatment-related AEs reported in >10% of patients in arm A Supplementary Table S3. Treatment-related AEs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030fa3fc24f2ed0aaede5e6bfe9fd078
https://doi.org/10.1158/1078-0432.22464449
https://doi.org/10.1158/1078-0432.22464449
Autor:
B. Douglas Smith, Mirjana Zeremski, Walter Fiedler, Pau Montesinos, Michael Heuser, Mikkael A. Sekeres, Cristina Papayannidis, Geoffrey Chan, Caroline J. Hoang, Akil Merchant, Ashleigh O'Connell, Jorge E. Cortes, José Antonio Pérez-Simón, Weidong Wendy Ma, Thomas O’Brien, Brian Leber
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Annals of Hematology
instname
Annals of Hematology
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study